HEPATITIS C: THE CURRENT STATE OF THE PROBLEM

dc.contributor.authorRakhmonov R. N.
dc.contributor.authorG’aybullayev Sh. F.
dc.contributor.authorNe’matov H. A.
dc.date.accessioned2025-12-29T17:57:19Z
dc.date.issued2025-01-31
dc.description.abstractThe article provides a generalized overview of modern virological, diagnostic, and therapeutic aspects of hepatitis C and discusses the latest achievements in this field. Standard therapy for chronic hepatitis C with pegylated forms of interferon-α and ribavirin leads to viral elimination in 40-50% of patients infected with HCV genotype 1 and in 80% of patients infected with HCV genotypes 2 and 3. Today, based on a better understanding of the molecular virology and pathogenesis of hepatitis C, new antiviral therapy strategies are being developed, which are likely to complement existing treatment options in the near future.
dc.formatapplication/pdf
dc.identifier.urihttps://webofjournals.com/index.php/5/article/view/3092
dc.identifier.urihttps://asianeducationindex.com/handle/123456789/24343
dc.language.isoeng
dc.publisherWeb of Journals Publishing
dc.relationhttps://webofjournals.com/index.php/5/article/view/3092/3054
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.sourceWeb of Medicine: Journal of Medicine, Practice and Nursing ; Vol. 3 No. 1 (2025): WOM; 339-347
dc.source2938-3765
dc.subjectHepatitis C, pegylated interferon-α, ribavirin, liver transplantation, sporadic hepatitis C.
dc.titleHEPATITIS C: THE CURRENT STATE OF THE PROBLEM
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typePeer-reviewed Article

item.page.files

item.page.filesection.original.bundle

pagination.showing.labelpagination.showing.detail
loading.default
thumbnail.default.alt
item.page.filesection.name
n_2025_hepatitis_c_the_current_state_of_the_pro.pdf
item.page.filesection.size
316.47 KB
item.page.filesection.format
Adobe Portable Document Format

item.page.collections